HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report
Journal of Cellular and Molecular Medicine · 2023
DOI: 10.1111/jcmm.17647 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Krzysztof Lewandowski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Multiple Myeloma, Myeloproliferative Disorders. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Out of BCR‐ABL negative myeloproliferative neoplasm (MPNPh − ) patients, 3%–14% display a concomitant monoclonal gammopathy of unknown significance (MGUS). In most cases, the diagnosis of plasma cell dyscrasia is either synchronous with that of MPNPh − or occurs later on. We present a 50‐year‐old patient with type 2 CALR Lys385Asnfs*47 mutation positive essential thrombocythemia (ET) who developed symptomatic multiple myeloma (MM) 13 years after the diagnosis of ET during PEG‐INF2α treatment. The NGS study performed at the time of the MM diagnosis revealed the HRAS Val14Gly/c.41T〉G mutation and the wild type CALR , JAK2 and MPL gene sequence. In the presented case, the complete molecular remission of ET was achieved after 16 months of PEG‐INF2α treatment. The origin of MM cells in MPNPh − patients remains unknown. Published data suggests that type 2 CALRins5 up‐regulate the ATF6 chaperone targets in hematopoietic cells and activate the inositol‐requiring enzyme 1α‐X‐box‐binding protein 1 pathway of the unfolded protein response (UPR) system to drive malignancy. It cannot be excluded that endoplasmic reticulum stress induced by the increased ATF6 resulted in an abnormal redox homeostasis and proteostasis, which are factors linked to MM. The presented case history and the proposed mechanism of mutant CALR interaction with UPR and/or ATF6 should initiate the discussion about the possible impact of the mutant CALR protein on the function and genomic stability of different types of myeloid cells, including progenitor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
- Department of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland.
- NanoBioMedical Centre, Adam Mickiewicz University in Poznań, Poznań, Poland.
- Department of Clinical Pathology, Poznań University of Medical Sciences, Poznań, Poland.
- Laboratory of Genomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
ORCID-Profile: Krzysztof Lewandowski, Zuzanna Kanduła, Marcin Machnicki, Kinga Gwóźdź-Bąk, Anna Płotka, Łucja Przysiecka, Piotr Kozłowski, Tomasz Stokłosa
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Lewandowski, K., Kopydłowska, A., Kanduła, Z., Sankowski, B., Machnicki, M., Barańska, M., Gwóźdź-Bąk, K., Kubicki, T., Płotka, A., Przysiecka, Ł., Dworacki, G., Kozłowski, P., & Stokłosa, T. (2023). HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17647
Vancouver
Lewandowski K, Kopydłowska A, Kanduła Z, Sankowski B, Machnicki M, Barańska M, et al. HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17647
BibTeX
@article{Lewandowski2023,
author = {Lewandowski, Krzysztof and Kopydłowska, Agata and Kanduła, Zuzanna and Sankowski, Bartłomiej and Machnicki, Marcin and Barańska, Marta and Gwóźdź-Bąk, Kinga and Kubicki, Tadeusz and Płotka, Anna and Przysiecka, Łucja and Dworacki, Grzegorz and Kozłowski, Piotr and Stokłosa, Tomasz},
title = {HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
doi = {10.1111/jcmm.17647}
}
EUVIMED